Referanslar

1. Shakespeare W. Hip, buttock and groin pain. In: Murtagh, John ed. General practice. 5 th ed. Australia, DC: Mc-Graw-Hill Australia Pty Ltd; 2011. p679-90.
2. Ahuja V, Thapa D, Patial S, Chander A, Ahuja A. Chronic hip pain in adults: current knowledge and future prospective. J Anaesthesiol Clin Pharmacol. 2020;36(4):450-57. [Crossref]  [PubMed]  [PMC]
3. Wians FH. Clinical laboratory tests: which, why, and what do the results mean? Laboratory Medicine. 2009;40(2):105-13. [Crossref]
4. Khattak ZE, El Sharu H, Bhutta BS. Overview on Ordering and Evaluation of Laboratory Tests. 2023 Aug 17. In: Stat-Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. [Link]
5. Van Paassen P, Damoiseaux J, Tervaert JWC. Laboratory assessment in musculoskeletal disorders. Best Pract Res Clin Rheumatol. 2003;17(3):475-94. [Crossref]  [PubMed]
6. Waits JB. Rational use of laboratory testing in the initial evaluation of soft tissue and joint complaints. Prim Care. 2010;37(4):673-89. [Crossref]  [PubMed]
7. Akdam İY, Şentürk T. Akut Faz Reaktanları. Turkiye Klinikleri Rheumatology-Special Topics. 2013;6(2):2-5. [Link]
8. Markanday A. Acute phase reactants in infections: evidence-based review and a guide for clinicians. Open Forum Infect Dis. 2015;2(3):ofv098. [Crossref]  [PubMed]  [PMC]
9. Akkuş İ, Kaçmaz B. Acute phase reactants. Intercont J Int Med.. 2024;2(3):74-6. [Crossref]
10. De Souza Miyahara H, Helito CP, Oliva GB, Aita PC, Croci AT, Vicente JRN. Clinical and epidemiological characteristics of septic arthritis of the hip, 2006 to 2012, a seven-year review. Clinics (Sao Paulo). 2014;69(7):464-8. [Crossref]  [PubMed]
11. Berger CE, Kröner AH, Minai-Pour MB, Ogris E, Engel A. Biochemical markers of bone metabolism in bone marrow edema syndrome of the hip. Bone. 2003;33(3):346-51. [Crossref]  [PubMed]
12. Ruparelia N, Ahmadi H, Cobiella C. Metastatic adenocarcinoma of the colon presenting as a monarthritis of the hip in a young patient. World J Surg Oncol. 2006;4:95. [Crossref]  [PubMed]  [PMC]
13. Monteserin L, Mesa A, Fernandez-Garcia MS, Gadanon-Garcia A, Rodriguez M, Varela M. Bone metastases as initial presentation of hepatocellular carcinoma. World J Hepatol. 2017;9(29):1158-65. [Crossref]  [PubMed]  [PMC]
14. Aapro M, Launay-Vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treat Rev. 2012;38(3):235-40. [Crossref]  [PubMed]
15. Santoro D, Satta E, Messina S, Costantino G, Savica V, Bellinghieri G. Pain in end-stage renal disease: a frequent and neglected clinical problem. Clin Nephrol. 2013;79(Suppl 1):S2-S11. [Crossref]
16. Alhassani RY, Bagadood RM, Balubaid RN, Barno HI, Alahmadi MO, Ayoub NA. Drug therapies affecting renal function: an overview. Cureus. 2021;13(11):e19924. [Crossref]
17. Denton J. Synovial fluid analysis in the diagnosis of joint disease. Diagnostic Histopathology. 2012;18(4):159-68. [Crossref]
18. Courtney P, Doherty M. Joint aspiration and injection and synovial fluid analysis. Best Pract Res Clin Rheumatol. 2013;27(2):137-69. [Crossref]  [PubMed]
19. Gerlag DM, Tak PP. How to perform and analyse synovial biopsies. Best Pract Res Clin Rheumatol. 2013;27(2):195-207. [Crossref]  [PubMed]
20. Mathews CJ, Weston VC, Jones A, Field M, Coakley G. Bacterial septic arthritis in adults. Lancet. 2010;375(9717):846-55. [Crossref]  [PubMed]
21. Brown CR, Samade R, Turnquist E, Mickley J, Lynch D, Larkin KT, et al. Assessment for septic arthritis in immunocompetent and immunocompromised patients: A single-institution study. J Am Acad Orthop Surg. 2022;30(1):27-35. [Crossref]
22. Hariharan P, Kabrhel C. Sensitivity of erythrocyte sedimentation rate and C-reactive protein for the exclusion of septic arthritis in emergency department patients. J Emerg Med. 2011;40(4):428-31. [Crossref]  [PubMed]
23. Thornton L, Ormsby N, Allgar V, Thomas G. Can C-reactive protein be used to predict acute septic arthritis in the adult population? South Med J. 2019;112(2):108-11. [Crossref]  [PubMed]
24. Jain S, Tittal P, Rohilla N, Sud A, Yadav C, Kanojia RK, et al. Acute septic arthritis revisited: a prospective study in 93 patients correlating C-reactive protein levels with duration of intravenous antibiotic therapy, clinical and radiological outcomes. Eur J Orthop Surg Traumatol.2009;19:447-55. [Crossref]
25. Peltola H, Vahvanen V, Aalto K. Fever, C-reactive protein, and erythrocyte sedimentation rate in monitoring recovery from septic arthritis: a preliminary study. J Pediatr Orthop. 1984;4(2):170-4. [Crossref]  [PubMed]
26. Carpenter CR, Schuur JD, Everett WW, Pines JM. Evidence-based diagnostics: adult septic arthritis. Acad Emerg Med. 2011;18(8):781-96. [Crossref]  [PubMed]  [PMC]
27. Madi S, Natarajan S, Murali S, Pandey V, Acharya K. A 10 year clinical, laboratory and arthroscopic data analysis of bacterial septic arthritis of adult native knee: a hospital-based study. Journal of Arthroscopy and Joint Surgery. 2020;7(4):216-23. [Crossref]
28. Earwood JS, Walker TR, Sue GJ. Septic arthritis: diagnosis and treatment. Am Fam Physician. 2021;104(6):589-97. [PubMed]
29. Berthoud O, Coiffier G, Albert J-D, Gougeon-Jolivet A, Goussault C, Bendavid C, et al. Performance of a new rapid diagnostic test the lactate/glucose ratio of synovial fluid for the diagnosis of septic arthritis. Joint Bone Spine. 2020;87(4):343-50. [Crossref]  [PubMed]
30. Varady NH, Schwab P-E, Kheir MM, Dilley JE, Bedair H, Chen AF. Synovial fluid and serum neutrophil-to-lymphocyte ratio: novel biomarkers for the diagnosis and prognosis of native septic arthritis in adults. J Bone Joint Surg Am. 2022;104(17):1516-22. [Crossref]  [PubMed]
31. Imagama T, Tokushige A, Seki K, Seki T, Nakashima D, Ogasa H, et al. Early diagnosis of septic arthritis using synovial fluid presepsin: A preliminary study. J Infect Chemother. 2019;25(3):170-4. [Crossref]  [PubMed]
32. Couderc M, Pereira B, Mathieu S, Schmidt J, Lesens O, Bonnet R, et al. Predictive value of the usual clinical signs and laboratory tests in the diagnosis of septic arthritis. CJEM. 2015;17(4):403-10. [Crossref]  [PubMed]
33. Mandl P, D'Agostino MA, Navarro-Compán V, Geßl I, Sakellariou G, Abhishek A, et al. 2023 EULAR recommen- dations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice. Ann Rheum Dis. 2024;83(6):752-59. [Crossref]  [PubMed]  [PMC]
34. Tao H, Mo Y, Liu W, Wang H. A review on gout: Looking back and looking ahead. Int Immunopharmacol. 2023;117:109977. [Crossref]  [PubMed]
35. Cha Y, Lee J, Choy W, Lee JS, Lee HH, Chae D-S. Pathophysiology and treatment of gout arthritis; including gout arthritis of hip joint: a literature review. Hip Pelvis. 2024;36(1):1-11. [Crossref]  [PubMed]  [PMC]
36. Di Matteo A, Filippucci E, Cipolletta E, Musca A, Carotti M, Mashadi Mirza R, et al. Hip involvement in patients with calcium pyrophosphate deposition disease: potential and limits of musculoskeletal ultrasound. Arthritis Care Res (Hoboken). 2019;71(12):1671-7. [Crossref]  [PubMed]
37. Mukhopadhyay S, Abhijit G, Perera A. Monoarticular pseudogout of the hip presenting as septic arthritis:a case report. Acta Orthop Traumatol Turc. 2011;45(3):200-2. [Crossref]  [PubMed]
38. Fua T-P, Lee YHD. Acute Hip Pain-A Forgotten Cause. International Journal of Clinical Medicine. 2016;7(3):177-81. [Crossref]
39. Dalbeth N, Choi HK, Joosten LA, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout (primer). Nat Rev Dis Primers. 2019;5(1):69. [Crossref]  [PubMed]
40. Wu H, Zhou H, Chen P. Correlation of neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and mean platelet volume (MPV) with gout activity: a monocentric and retrospective study. Medicine (Baltimore). 2022;101(35):e30242. [Crossref]  [PubMed]  [PMC]
41. Kadiyoran C, Zengin O, Cizmecioglu HA, Tufan A, Kucuksahin O, Cure MC, et al. Monocyte to lymphocyte ratio, neutrophil to lymphocyte ratio, and red cell distribution width are the associates with gouty arthritis. Acta Medica (Hradec Kralove). 2019;62(3):99-104. [Crossref]  [PubMed]
42. Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective-A review. J Adv Res. 2017;8(5):495-511. [Crossref]  [PubMed]  [PMC]
43. López-Medina C, Castro-Villegas MC, Collantes-Estévez E. Hip and shoulder involvement and their management in axial spondyloarthritis: a current review. Curr Rheumatol Rep. 2020;22(9):53. [Crossref]  [PubMed]
44. Ziadé N, El Hajj J, Rassi J, Hlais S, López-Medina C, Gamal SM, et al. Root joint involvement in spondyloarthritis: a post hoc analysis from the international ASAS-PerSpA study. Rheumatology (Oxford). 2022;61(2):667-78. [Crossref]  [PubMed]
45. Slouma M, Rahmouni S, Tbini H, Dhahri R, Saffar F, Bellali H, et al. Factors associated with hip involvement in spondyloarthritis: a retrospective study. ARP Rheumatol. 2022;1(4):278-85. [PubMed]
46. Maksymowych WP. Biomarkers in spondyloarthritis. Curr Rheumatol Rep. 2010;12(5):318-24. [Crossref]  [PubMed]
47. Poddubnyy D, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64(5):1388-98. [Crossref]  [PubMed]
48. Reveille JD. Spondyloarthritis. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, eds. Clinical Immunology. 5 th ed. Elsevier; 2019. p.769-87. [Crossref]
49. Zimba O, Kocyigit BF, Korkosz M. Diagnosis, monitoring, and management of axial spondyloarthritis. Rheumatol Int. 2024;44(8):1395-407. [Crossref]  [PubMed]  [PMC]
50. Eroğlu DŞ, Torgutalp M, Sezer S, Yayla ME, Özel M, Turgay TM, et al. Complete blood count derived haematological parameters do not correlate with disease activity in patients with radiographic axial spondyloarthritis. J Turk Soc Rheumatol. 2021;13(1):6-11. [Crossref]
51. Kaplan H, Cengiz G, Şaş S, Eldemir YÖ. Is the C-reactive protein-to-albumin ratio the most remarkable simple inflammatory marker showing active disease in patients with axial spondyloarthritis, psoriatic arthritis, and rheumatoid arthritis? Clin Rheumatol. 2023;42(11):2959-69. [Crossref]  [PubMed]
52. D'Angelo S, Carriero A, Gilio M, Ursini F, Leccese P, Palazzi C. Safety of treatment options for spondyloarthritis: a narrative review. Expert Opin Drug Saf. 2018;17(5):475-86. [Crossref]  [PubMed]
53. Carvalho PD, Machado PM. How to investigate: early axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2019;33(4):101427. [Crossref]  [PubMed]
54. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1- ii44. [Crossref]  [PubMed]
55. Priyathersini N, Shanmugam SG, Devi SS, Dandapani MPC, Rajendiran S, D'Cruze L. Detection of Human leukocyte antigen B27 by flowcytometry in patients with suspected ankylosing spondylitis in a tertiary care centre. Cureus. 2021;13(2):e13560. [Crossref]
56. Lachiewicz PF. Rheumatoid arthritis of the hip. J Am Acad Orthop Surg. 1997;5(6):332-38. [Crossref]  [PubMed]
57. Suto T, Okamura K, Yonemoto Y, Okura C, Tsushima Y, Takagishi K. Prediction of large joint destruction in patients with rheumatoid arthritis using 18F-FDG PET/CT and disease activity score. Medicine (Baltimore). 2016;95(7):e2841. [Crossref]  [PubMed]  [PMC]
58. Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014;16(1):R40. [Crossref]  [PubMed]  [PMC]
59. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. [Crossref]  [PubMed]
60. Taha SI, Samaan SF, Ibrahim RA, Moustafa NM, El-Sehsah EM, Youssef MK. Can complete blood count picture tell us more about the activity of rheumatological diseases? Clin Med Insights Arthritis Musculoskelet Disord. 2022;15:11795441221089182. [Crossref]  [PubMed]  [PMC]
61. Rigby WF, Lampl K, Low JM, Furst DE. Review of routine laboratory monitoring for patients with rheumatoid arthritis receiving biologic or nonbiologic DMARDs. Int J Rheumatol. 2017;2017:9614241. [Crossref]  [PubMed]  [PMC]
62. Pincus T, Sokka T. Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am. 2009;35(4):731-4. [Crossref]  [PubMed]
63. Van Delft MA, Huizinga TW. An overview of autoantibodies in rheumatoid arthritis. J Autoimmun. 2020;110:102392. [Crossref]  [PubMed]
64. Zacher J, Gursche A. 'Hip'pain. Best Pract Res Clin Rheumatol. 2003;17(1):71-85. [Crossref]  [PubMed]
65. Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C. Pathogenesis, diagnosis and management of polymyalgia rheumatica. Drugs Aging. 2019;36(11):1015-26. [Crossref]  [PubMed]
66. Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2012;64(4):943-54. [Crossref]  [PubMed]
67. Jung JY, Lee E, Suh CH, Kim HA. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica. J Clin Lab Anal. 2019;33(9):e23000. [Crossref]  [PubMed]  [PMC]
68. Florescu MM, Bobircă F, Florescu A, Pădureanu V, Bobircă A, Ciurea PL, et al. Polymyalgia rheumatica: An update. Exp Ther Med. 2023;26(6):543. [Crossref]  [PubMed]  [PMC]
69. Hysa E, Castagna A, Manzo C. Liver involvement in polymyalgia rheumatica and giant cell arteritis. Reumatologia. 2020;58(6):444-5. [Crossref]  [PubMed]  [PMC]
70. Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet. 2013;381(9860):63-72. [Crossref]  [PubMed]
71. Kaya M. Kalçanın Primer Malign Kemik Tümörleri. Özmanevra R, Işın Y, Kara YS, Yaman F, Demirkıran ND, Editörler. Erişkinlerde Kalça Hastalıkları ve Tedavisinde Güncel Yaklaşımlar. Akademisyen Kitabevi; 2020. p.355-64. [Link]
72. Bloem JL, Reidsma II. Bone and soft tissue tumors of hip and pelvis. Eur J Radiol. 2012;81(12):3793-801. [Crossref]  [PubMed]
73. Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance. World J Gastroenterol. 2019;25(31):4383-404. [Crossref]  [PubMed]  [PMC]
74. Robinson TP, Hamidi T, Counts B, Guttridge DC, Ostrowski MC, Zimmers TA, et al. The impact of inflammation and acute phase activation in cancer cachexia. Front Immunol. 2023;14:1207746. [Crossref]  [PubMed]  [PMC]
75. Orr WS, Malkas LH, Hickey RJ, Sandoval JA, Veas F. Acute Phase Proteins as Cancer Biomarkers. In: Veas F, ed. Acute Phase Proteins as Early Non-Specific Biomarkers of Human and Veterinary Diseases. 1st ed. Croatia, DC: Intech; 2011. p.1-20. [Link]
76. Gianakos AL, Patel JN, Miller JM, Sonnylal L, Wittig JC. Metastatic Disease, Myeloma, and Lymphoma Affecting the Hip. J Hip Surg. 2019;3:34-40. [Crossref]
77. Ündar L. Multipl Miyelom: Tanı. 35. Ulusal Hematoloji Kongresi 2009: Antalya, Türkiye, 7-10 Ekim 2009. p.89-92. [Link]
78. Annibali O, Petrucci M, Santini D, Bongarzoni V, Russano M, Pisani F, et al. Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference? J Bone Oncol. 2020;26:100338. [Crossref]  [PubMed]  [PMC]
79. Liu D, Xiao W-f, Li Y-s. The Diagnostic and Prognostic Value of Synovial Fluid Analysis in Joint Diseases. Methods Mol Biol. 2023;2695:295-308. [Crossref]  [PubMed]
80. Hall M, van der Esch M, Hinman RS, Peat G, de Zwart A, Quicke J, et al. How does hip osteoarthritis differ from knee osteoarthritis? Osteoarthritis Cartilage. 2022;30(1):32-41. [Crossref]  [PubMed]
81. Lespasio MJ, Sultan AA, Piuzzi NS, Khlopas A, Husni ME, Muschler GF, et al. Hip osteoarthritis: a primer. Perm J. 2018;22:17-084. [Crossref]  [PubMed]  [PMC]
82. Oliviero F, Scanu A, Galozzi P, Ramonda R. Synovial fluid analysis to identify osteoarthritis. J Vis Exp. 2022;(188). [Crossref]  [PubMed]
83. Jain A, Clamp K. Adult hip pain. InnovAiT. 2020;13(1):21-7. [Crossref]
84. Tsai H-L, Chang J-W, Lu J-H, Liu C-S. Epidemiology and risk factors associated with avascular necrosis in patients with autoimmune diseases: a nationwide study. Korean J Intern Med. 2022;37(4):864-76. [Crossref]  [PubMed]  [PMC]
85. Shaharir SS, Chua SH, Mohd R, Mustafar R, Noh MM, Shahril NS, et al. Risk factors for symptomatic Avascular Necrosis (AVN) in a multi-ethnic Systemic Lupus Erythematosus (SLE) cohort. PLoS One. 2021;16(3):e0248845. [Crossref]  [PubMed]  [PMC]
86. Huffman K, Bowers J, Dailiana Z, Huebner J, Urbaniak J, Kraus V. Synovial fluid metabolites in osteonecrosis. Rheumatology (Oxford). 2007;46(3):523-8. [Crossref]  [PubMed]
87. Rabquer BJ, Tan GJ, Shaheen PJ, Haines III GK, Urquhart AG, Koch AE. Synovial inflammation in patients with osteonecrosis of the femoral head. Clin Transl Sci. 2009;2(4):273-8. [Crossref]  [PubMed]  [PMC]